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AbstrACt
Objectives There is considerable interest in reducing the 
cost of clinical trials. Linkage of trial data to administrative 
datasets and disease-specific registries may improve trial 
efficiency, but it has not been reported in resuscitation 
trials conducted in the UK. To assess the feasibility of using 
national administrative and clinical datasets to follow 
up patients transported to hospital following attempted 
resuscitation in a cluster randomised trial of a mechanical 
chest compression device in out-of-hospital cardiac arrest.
Methods Hospital data on trial participants were 
requested from Hospital Episode Statistics (HES), the 
Intensive Care National Audit and Research Centre, and 
Myocardial Ischaemia National Audit Project and National 
Audit of Percutaneous Coronary Interventions, using unique 
patient identifiers. Linked data were received between 
June 2014 and June 2015.
results Of 4471 patients randomised in the pre-hospital 
randomised assessment of a mechanical compression 
device in cardiac arrest (PARAMEDIC) trial, 2398 (53.6%) 
were not known to be deceased at emergency department 
arrival and were eligible for linkage. We achieved an 
overall match rate of 86.7% in the combined HES accident 
and emergency, inpatient and critical care dataset, 
with variable match rates (4.2%–80.4%) in individual 
datasets. Patient demographics, cardiac arrest-related 
characteristics and major outcomes were predominantly 
similar between HES matched and unmatched groups, in 
the linkage apart from location, response time and return 
of spontaneous circulation (ROSC) at handover.
Conclusions This study shows that it is feasible to track 
patients from the prehospital setting through to hospital 
admission using routinely available administrative datasets 
with a moderate to high degree of success. This approach 
has the potential to complement the trial data with the 
demographic and clinical management information about 
the studied cohort, as well as to improve the efficiency and 
reduce the costs of follow-up in cardiac arrest trials.
Clinical trial registration ISRCTN08233942; Post-results.
bACkgrOund 
Well conducted and reported randomised 
controlled trials (RCTs) are considered the gold 
standard in evaluation of new or established 
clinical interventions. In cardiac arrest resus-
citation science, only a small minority (1%) of 
contemporary international guideline recom-
mendations are based on the highest level of 
evidence from more than one RCT, meta-anal-
ysis of high quality RCTs or RCTs corroborated 
by high-quality registry studies.1 High-quality 
trials to address outcomes of interest to patients 
following cardiac arrest (eg, long-term survival, 
neurocognitive status and disability)2 are 
complex, labour intensive and expensive to 
perform. Many studies in cardiac arrest are 
therefore too small or inadequately conducted 
(with a predominance of observational studies 
which are prone to bias) to provide reliable esti-
mates of treatment effect or harm to patients. 
Consequently, for the majority of resuscitation 
interventions, there is a paucity of high-quality 
evidence. Funders (typically government agen-
cies) have called for proposals for low-cost, 
more efficient trials.3 
Traditional trial methods of patient 
tracking and data access in individual hospi-
tals is challenging with limited resources. 
strengths and limitations of this study
 ► First study evaluating the supplement of routinely 
collected administrative data in a cardiac arrest trial 
in the UK.
 ► Data linkage was made to different UK national 
registries.
 ► The matching reliability was suboptimal due to re-
laxed matching criteria, matching method and pos-
sible data quality issues.
 ► Routine data were not fully available for all trial pa-
tients transported to hospital.
 ► The findings of our study are not generalisable to 
facilitate trial recruitment since it was considered 
unrealistic in the clinical context of cardiac arrest.
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Cardiovascular medicine has attempted to improve the 
efficiency of the trial design by pioneering the concept 
of registry-based randomised trials, using clinical quality 
registries and administrative datasets. In the Thrombus 
Aspiration during ST-Segment Elevation Myocardial 
Infarction (TASTE) trial, undertaken in Sweden, both 
patient enrolment and follow-up were conducted using 
the Swedish Web System for Enhancement and Devel-
opment of Evidence-based Care in Heart Disease Eval-
uated According to Recommended Therapies registry.4 
On publication, this registry-based trial was hailed as 
the ‘next disruptive technology’ in clinical research and as a 
new clinical trial paradigm.5 6 Subsequent registry-based 
trials have been reported in a comparison of radial versus 
femoral access in women undergoing percutaneous 
coronary intervention in the USA7 and of supplemental 
oxygen versus ambient air in patients with suspected 
acute myocardial infarction in Sweden.8
To our knowledge, however, there are no reports of 
registry-based randomised trials in resuscitation science. 
However, should accessing registry data to ascertain 
outcomes in a prehospital cardiac arrest trial (eg, length 
of stay/patient pathways/survival status) to be feasible, 
this could be one way of significantly improving effi-
ciency and reducing costs of conducting high-quality 
randomised trials in resuscitation.
In the PARAMEDIC trial, the in-hospital data collection 
process was complex, expensive and labour intensive, with 
research paramedics visiting multiple hospitals across 
large geographical areas to extract data from hospital 
records. Patients transported to hospital following resus-
citation from cardiac arrest follow multiple clinical path-
ways depending on their clinical status and treatments. 
As hospital data are routinely collected and managed 
by national registries, using these registries could save 
resources and time in the in-hospital data collection and 
potentially reduce the burden on patients and relatives in 
the sensitive period following cardiac arrest.
This paper reports our assessment of the feasibility of 
linking data collected for the purposes of patient follow-up 
in a pragmatic, cluster RCT of a mechanical chest compres-
sion device undertaken in the UK prehospital setting, with 
large national administrative and specialist registries.
MethOds
The PARAMEDIC trial examined the effectiveness of 
LUCAS-2, a mechanical chest compression device, in 4471 
patients with out-of-hospital cardiac arrest (OHCA). The 
study was a cluster randomised trial whereby emergency 
medical service (EMS) vehicles were randomised to carry 
the LUCAS-2 device (intervention) or not (control). Full 
details of the trial protocol have been published previ-
ously.9 In summary, adults with OHCA where resuscita-
tion was attempted by EMS personnel and attended by 
a trial vehicle were included. Patients with traumatic 
cardiac arrest or suspected to be pregnant were excluded. 
Trial recruitment ran from 15 April 2010 to 10 June 2013. 
We have previously reported primary outcome (30-day 
survival),10 secondary outcomes,11 an economic analysis12 
and characteristics of patients who were not resuscitated.13
data sources
The PARAMEDIC trial used four sources of data that were 
linked to the trial dataset: UK National Health Service 
(NHS) Hospital Episodes Statistics (HES), Myocardial 
Ischaemia National Audit Project (MINAP),14 National 
Audit of Percutaneous Coronary Interventions (NAPCI)15 
and Case Mix Programme (CMP)16 to obtain data on 
hospital stay and treatment or procedures that trial 
patients received in hospital.
We used the MINAP, NAPCI and CMP data for the 
health economic analysis12 and long-term postadmission 
outcomes11 and to validate the hospital length of stay or 
stay in the intensive care (secondary outcomes for the 
efficacy part of the trial) and also to gain insight into the 
specifics of the treatment or procedures that trial patients 
received during their hospital stay. Characteristics of the 
registries are summarised in table 1.
Patient population
Patients (denominator) for this linkage study were 
patients from the PARAMEDIC trial who were trans-
ported to hospital by EMS and not known to be deceased 
(ie, documented as alive or unknown status) on arrival at 
the emergency department (ED).
Since NHS Digital (NHSD), responsible for HES, only 
provides annual data up to 1st April each year, no data 
on trial patients recruited on or after 1 April 2013 had 
any HES data returned for this data request. We therefore 
limited our analysis of the linked registry data to patients 
recruited to the PARAMEDIC trial between April 2010 
and March 2013.
study approvals
The PARAMEDIC trial was sponsored by the University 
of Warwick, UK. The study was conducted in accordance 
with the principles of Good Clinical Practice and the 
Mental Capacity Act (2005). Specific approval for access 
to personal data without consent and the data linkage 
reported in this paper was obtained from the Confi-
dentiality Advisory Group, part of the Health Research 
Authority (reference: ECC 2–02 (c)/2011). At the time 
of the study, this activity was undertaken by the National 
Information Governance Board for Health and Social 
Care Ethics and Confidentiality Committee.
Patient and public involvement
Patient and public representatives were invited to the Trial 
Steering Committee meetings during the development and 
conduct of the main trial. They agreed with the data collec-
tion via linkage to reduce the burden on patients and rela-
tives. They were regularly informed of this study and other 
trial outputs. The results of this study will be disseminated in 
different ways, including presentation on the publicly acces-
sible trial webpage.
 o
n
 O
ctober 28, 2019 by guest. Protected by copyright.
http://bmjopen.bmj.com/
BM
J O
pen: first published as 10.1136/bmjopen-2018-021519 on 28 July 2018. Downloaded from 
3Ji C, et al. BMJ Open 2018;8:e021519. doi:10.1136/bmjopen-2018-021519
Open access
data linkage procedure
Data access applications were submitted to national 
administrative and disease registries between 
2012 and 2014 to request patient case mix and clinical 
variables (online supplementary table 1). The following 
patient identifiers were sent to the NHSD, Intensive Care 
National Audit and Research Centre (ICNARC) and 
National Institute for Cardiovascular Outcomes Research 
(NICOR) to identify their clinical records: trial number, 
cardiac arrest date, ambulance service case number, 999 
call time, hospital name, hospital arrival time, hospital 
handover time, patient name, NHS number, home 
address and postcode. The trial data were linked to the 
two NICOR datasets (MINAP and NAPCI) on two sepa-
rate occasions by a different member of NICOR staff, 
which reassuringly generated the same results. Extracted 
anonymous data were encrypted and sent back to the trial 
team between June 2014 and June 2015.
Linked data may contain multiple, non-event-related 
hospital records within the requested linkage period. 
We first used patient cardiac arrest (trial event) date to 
identify the records with exactly matched admission/visit 
date in the respective data sources. However, event and 
admission dates could be different due to potential data 
definition discrepancies. For instance, a trial event could 
occur before midnight, and the patient was admitted to 
hospital after midnight. Therefore, we relaxed the date 
match criterion to a 5-day range (date of cardiac arrest 
with ±2 days). A matched record was redefined as if the 
admission/visit date falls in the range. We considered 
the range would be sufficiently large to mitigate against 
any date discrepancies in different sources and also be 
reasonably small to reduce the chance of mismatch in the 
case of early readmission. Where multiple records could 
be matched to a single trial event in the same routine 
dataset, separate rules were used to extract the retrieved 
information: (1) where a patient had multiple episodes 
in HES, only the one with recorded death or discharge 
date was retained. If a patient had not been discharged 
from hospital, the episode with latest ward admission 
date was used. (2) Where multiple admissions to inten-
sive care unit (ICU) were recorded in CMP, only the first 
ICU admission was linked to a trial event. (3) Since the 
MINAP dataset provided to us by NICOR only contained 
year and month of admission, only the earliest admission 
was used. (4) Only the first procedure was included for 
the linkage to the NAPCI registry data, since patients can 
have more than one interventional procedure (and thus 
another record) during the index admission.
data linkage rate
For HES data, we developed the linkage and match rate for 
linked and matched (or correctly linked) cases as follows:
  
HES linkage rate
=
N of patients with linked HES inpatient,
Critical care or A&E data
N of patients not known to be deceased at ED  
  
HES match rate
=
N of patients with matched (correctly linked) HES inpatient,
Critical care or A&E data
N of patients not known to be deceased at ED   
Table 1 Characteristics of registries, participation and case ascertainment
Registry/dataset Source Description
Participation and 
case ascertainment* 
during the trial period
Paramedic trial Warwick Clinical Trials 
Unit
Trial patient cohort that survived admission to a hospital. N/A
Hospital Episode 
Statistics
NHS Digital Collection of information on all NHS hospital inpatients, 
accident and emergency, critical care and outpatients that 
enables healthcare providers to be paid according to their 
levels of activity.
All hospitals.
Case ascertainment 
100%.
Case Mix 
Programme
Intensive Care 
National Audit and 
Research Centre
Audit of patient outcomes from all adult, general critical 
care units in England, Wales and Northern Ireland. Other 
specialist units, including neurosciences, cardiac and high 
dependency units, also participate.
Over 90% of critical 
care units.
Case ascertainment 
not reported.
Myocardial 
Ischaemia 
National Audit 
Project
National Institute 
for Cardiovascular 
Outcomes Research 
(NICOR)
National audit of patients with acute coronary syndrome 
admitted to all hospitals in England, Wales and Northern 
Ireland. Data are collected prospectively at each hospital 
by secure electronic system, electronically encrypted and 
transferred online to a central database.
All hospitals.
Case ascertainment 
not reported.
National Audit 
of Percutaneous 
Coronary 
Interventions
NICOR National audit of all percutaneous coronary 
intervention  (PCI) procedures from NHS and non-NHS 
hospitals in the UK.
All hospitals.
Case ascertainment 
97%.
*Case ascertainment – rate (eg, %) of eligible cases included in a registry/database.
NHS, National Health Service.
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n of patients not known to be deceased at ed
Similar equations were used to determine the rates for 
each of the datasets, that is, MINAP, NAPCI and CMP. 
As we were not able to confirm which patient should 
actually be collected in these datasets, we employed 
same denominator used in the above equations.
data linkage quality
Match rank is an indicator used in HES to show the confi-
dence of match: 1 suggests the best match and 8 suggests 
the worst. Levels 1–3 appear to be of high quality as cases 
are matched based on a combination of unique NHS 
number and data of date of birth, sex and home post-
code. The quality of linkage in matched HES was there-
fore summarised on the basis of percentage of levels 1–3.
data representativeness
Data representativeness was assessed in two compari-
sons. The first comparison intended to assess whether 
the patients with correctly linked (ie, matched) HES 
data could be representative of the trial population. It 
was carried out in patients with and without matched 
HES Inpatient, Critical Care or A&E data (comparison 
1). The second comparison intended to assess the differ-
ence between two critical care data sources. We were not 
able to compare data from these two sources directly as 
some patient care data were collected in both databases. 
Hence, we split the patients by their linked data sources 
and made the comparison between patients with HES 
Critical Care only, with CMP data only and with both HES 
Critical Care and CMP data (comparison 2).
For both comparisons, we compared patient and event 
characteristics between the datasets. Continuous variables 
were compared using Mann-Whitney U test in compar-
ison 1 and Kruskal-Wallis test in comparison 2. Categor-
ical variables were compared using the χ2 test. A two-sided 
p value <0.05 was considered statistically significant. All 
analyses were conducted in SAS V.9.3 (SAS Institute, Cary, 
North Carolina, USA).
data security and destruction
We followed the Warwick Clinical Trials Unit Standard 
Operating Procedures for data storage, transfer and data 
sharing. The data were retained and destroyed in accor-
dance with relevant regulations and the University of 
Warwick’s Data Sharing Agreements.
results
In the PARAMEDIC trial, 2695 patients were transported 
to hospital and not known to be deceased at ED. Of these, 
2398 (89.0%) were recruited between April 2010 and 
March 2013 and were therefore included in this study 
(referred to as ‘linkage patients’). The data requests to 
NHSD, ICNARC and NICOR retrieved different numbers 
of patient clinical records.
summary of the linkage
The flow chart of the linkage to HES is shown in figure 1. 
The linkage patients were grouped into ICU admitted 
(patients with matched HES Critical Care data) and 
not admitted (patients with other matched HES data). 
Meanwhile, patients with matched CMP data were also 
summarised in the flow chart. This presented a compar-
ison between CMP and HES Critical Care. Three hundred 
and three patients were matched in both CMP and HES 
Critical Care. Overall, the linkage to HES data achieved 
a match rate of 86.7% (2079 of 2398) with allowed varia-
tion in dates (date of cardiac arrest with ±2 days), slightly 
improved from the use of exact date match approach 
(84.1%).
Linkage quality was high in matched cases: levels 1–3 
accounted for 97.9%. In unmatched cases, 91.5% (292 of 
319) had no linked HES data, and the rest, while linked 
with non-trial even related data, had a good match rank 
(≤3).
The summary of linkage and match rate in each dataset 
are shown in table 2. All datasets contained multiple 
linked records, indicating some patients had been linked 
to multiple admissions with possible multiple episodes. 
Among the 2398 linkage patients, individual match 
rate varied depending on the hospitalisation stage and 
received treatments. HES A&E had the highest individual 
match rate (80.4%). In the patients admitted to ICU, CMP 
provided 53 more matched patients with a lower propor-
tion of unmatched data in linked patients compared with 
HES Critical Care.
A summary of retrieved information for each linked 
dataset as well as the degree of data missingness for each 
field is available in the online supplementary materials. 
In online supplementary table 2, the trial patients that 
had not been matched to the HES records were similar 
to those that with matched records in age (mean age 
71.8 and 73.6, respectively), male (67.4% and 63.3%, 
respectively, were male). They were also similar between 
groups in initial cardiac arrest aetiology where most were 
of cardiac origin (85.3% and 85.9%, respectively) and 
in initial rhythm (shockable rhythm; 31.0% and 31.3%). 
Patients with unmatched data were more likely to have 
had a cardiac arrest in a public place (27.9%) compared 
with of those with matched records (16%), witnessed 
by bystander (53.3% vs 46.3%) and had longer EMS 
response time (7.2 min vs 6.1 min). Online supplemen-
tary table 3 illustrates the comparison of demographic 
and event characteristics of patients with matched HES 
Critical Care and CMP data. Characteristics were similar 
in all three groups, except for a significant difference in 
the EMS response time.
disCussiOn
This study aimed to demonstrate the feasibility of 
collecting trial outcome data during patient follow-up in 
a prehospital cardiac arrest trial via linkage to national 
registries. We achieved an overall match rate of 86.7% in 
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2398 patients using HES data. The data linkage provided 
important administrative and additional clinical data 
that allowed extended analyses of the intervention effect 
and provided more details of patient journey in the trial. 
We also evaluated the representativeness of retrieved 
HES and CMP data by comparing patient and trial event 
characteristics. No substantial difference was found in 
patients with and without matched HES Inpatient, Crit-
ical Care or A&E data, as well as in patients with matched 
HES Critical Care only, CMP only and both datasets.
This was the first study evaluating the supplement of 
routinely collected administrative data in a cardiac arrest 
Figure 1 Linkage match rate and flowchart of patients retrieving HES or CMP data. A&E, accident and emergency; CMP, Case 
Mix Programme; ED, emergency department; HES, Hospital Episodes Statistics; ICNARC, Intensive Care National Audit and 
Research Centre; ICU, intensive care unit.
Table 2 Summary of linked PARAMEDIC trial patients to the respective registry databases
Data source Dataset Number of linked records
Number of linked patients 
(linkage rate)*
Number of matched 
patients (match rate)*
NHSD HES Inpatient 12 875 1617 (67.4) 771 (32.2)
HES Critical Care 545 433 (18.1) 354 (14.8)
HES A&E 6434 2186 (91.2) 1927 (80.4)
Overall 19 854 2277 (95.0) 2079 (86.7)
ICNARC CMP 435 410 (17.1) 407 (17.0)
NCAP MINAP 244 218 (9.1) 182 (7.6)
PCI 153 128 (5.3) 101 (4.2)
*Percentage is calculated using the number in the column divided by 2398 linkage patients.
A&E, accident and emergency; CMP, Case Mix Programme; HES, Hospital Episodes Statistics; ICNARC, Intensive Care National Audit and 
Research Centre; NCAP,National Cardiac Audit Programme; MINAP, Myocardial Ischaemia National Audit Project; NHS, National Health 
Service; PCI, Percutaneous Coronary Intervention; NHSD, NHS Digital.
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trial in the UK. Our match rate was in line with obser-
vational studies linking EMS data to hospital records17–20 
and data validation studies.21 Our experience suggests 
it is feasible to obtain relevant data from administrative 
databases in a cardiac arrest trial. In addition to the high 
match rate reported in this paper, the matched data 
are deemed to be sufficiently representative of the trial 
population. The comparison between patients with and 
without matched HES showed low level of imbalance of 
event characteristics. We have found similar results in the 
matched ICU data.
The unmatched cases were likely to be associated 
with missing or inaccurate data. Data quality could be 
at increased risk due to the challenging circumstances 
of cardiac arrest and complexity of patient handling 
following hospital arrival. In addition, routine data in 
the chosen registries are not systematically adjudicated. 
Lack of clinical engagement may compromise the case 
ascertainment and data quality,22 leading to suboptimal 
linkage. NHSD employs deterministic and probabilistic 
methods in the data linkage. The latter calculates prob-
ability weight based on combinations of linkage variables 
and determines linkage based on a cut-off threshold. 
Although this method largely improves the linkage, it 
could incorrectly link record pairs and miss valid ones, 
undermining the reliability of linkage.
Linkage to individual routine datasets resulted in vari-
able match rates. HES A&E generated the highest rate of 
80.4% as most patients were taken by EMS to ED for assess-
ment before being admitted to specialist hospital units. 
Other rates reflected the proportion of specific groups 
of patients in the linkage. The CMP, MINAP and NAPCI 
registries are focused on selected patients with a specific 
diagnosis and/or requiring specialist care, reflected 
in strict inclusion and exclusion criteria; for example, 
MINAP comprises data on patients with suspected and/
or confirmed acute coronary syndrome, NAPCI on inter-
ventional cardiology, while CMP registry collects data on 
patients admitted to critical care/ICUs within any given 
hospital. In this study, MINAP and NAPCI generated 
9.1% and 5.3%, respectively. Patients who die in the ED 
are less likely to be recorded on MINAP, and only those 
patients receiving interventional cardiology are recorded 
in NAPCI.
Use of routine data has the potential to reduce the 
costs of conducting trials. The cost of the TASTE trial 
was reported as US$300 000, or approximately $50 per 
patient,4 2% of the cost of a traditional randomised 
trial, but differs from the PARAMEDIC trial in that we 
did not use registry data to identify and recruit patients 
in the challenging and time-pressured setting of OHCA. 
In the West of Scotland Coronary Prevention trial, data 
linkage reduced costs of long-term follow-up to less 
than 1% of trial budget.23 However, the time cost of 
linkage could be unrealistic for some trials. Linkage for 
the PARAMEDIC trial took up to 3 years from applica-
tion to the trial team obtaining the data. It has been 
suggested that NHSD, which performed the linkage to 
HES for our study, was overwhelmed with data linkage 
applications.24 This may limit the usefulness of adminis-
trative data in trials with funder-imposed deadlines for 
completion.
limitations
Our study had several limitations. The matching reliability 
was suboptimal due to relaxed matching criteria (using 
range of event date), matching methods and poten-
tial issues of data quality and completeness, common 
to administrative data. Bohensky et al25 conducted an 
evidence synthesis of data linkage studies and identified 
factors such as suboptimal or incomplete linkage leading 
to systematic bias. They considered the participant or 
population characteristics that can influence the validity 
and completeness of data linkage and may in turn lead to 
systematic bias in reporting. They reported variation in 
quality of data linkage across geographical/hospital sites, 
which could be due to high staff turnover or not sufficient 
resources allocated to the data collection and/or coding. 
We have not considered such variations in this study, but 
overall match quality was high in the matched cases.
Second, routine data were not fully available for all 
patients transported to hospital. Some patients were not 
included in the linkage as their data were not available 
in HES at the time of our data application. Although no 
substantial bias was shown, the generalisability of results 
could be limited. Several data fields were incomplete; 
for example, MINAP captures most ST elevation myocar-
dial infarction (STEMI) cases, but data for non-STEMI 
are less complete. We also cannot confirm how many 
patients required specialist care and should be included 
in non-HES datasets. Therefore, we were unable to assess 
and report the impact of unmatched cases in in the 
linkage to these registries.
Third, we used the first matched admission without 
considering repeated or later admissions. We were there-
fore unlikely to fully describe patients’ hospital pathway 
based on matched information.
Fourth, our focus for the present study was on assessing 
the feasibility of using administrative data for purposes 
of follow-up. We did not assess the utility of administra-
tive data to facilitate recruitment of trial patients since 
this was considered unrealistic in the clinical context of 
cardiac arrest.
Fifth, we did not assess the financial cost of manual data 
collection at hospitals to compare with the cost of the use 
of registries in the trial linkage.
recommendations
Based on our experience, we made the following recom-
mendations to improve the use of data linkage in trials:
1. When planning a trial using linkage to administrative 
registries, careful planning is required to assess avail-
ability of the required data. Linkage to routine data 
in different jurisdictions or multiple registries requires 
separate applications for data release and may be sub-
ject to data availability.
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2. Trialists need to be mindful of prolonged processes 
for regulatory approvals, data release and validation. 
These processes may extend beyond trial funding.
3. Data linkage is a lengthy often unpredictable process 
in the application stage, possibly due to the restricted 
capacity of registries funded primarily to assess quality 
of care. Most registries in the NHS are funded as na-
tional audits and do not have sufficient resources for 
the timely processing of data sharing requests.
4. The quality of routinely collected data in the national 
registries may be inferior to that collected using tra-
ditional trial processes. Registry data are collected in 
high volume with limited resources, and the valida-
tion process is unlikely to be as robust as in trials that 
are better resourced. Moreover, collected variables in 
registries are reviewed periodically and may change to 
reflect advances in clinical practice, which can impact 
on data completeness. Therefore, we suggest that tri-
alists use registry data as the main source of all in-hos-
pital data points and active data collection by a study 
team as an auxiliary approach to collect data for the 
unmatched patients.
5. It is common for registries to charge a fee for data re-
lease, which should be costed in to trial budgets.
COnClusiOns
This study shows that it is feasible to track patients from 
the prehospital setting through to hospital admission 
using routinely available administrative datasets with a 
moderate to high degree of success. This may improve the 
efficiency and reduce the costs for longer term follow-up 
in cardiac arrest trials.
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